Medica Group Plc (LSE: MGP, 'Medica' or the 'Company'), the UK market leader in teleradiology services, and Qure.ai, a global leader in artificial intelligence (AI) solutions for radiology, announce a strategic partnership to develop AI tools for prioritisation and improved efficiency of radiology scan workload.
Under the terms of the agreement, Medica will partner with Qure.ai in two important areas:
The first is to launch a decision support tool for CT (computed tomography) head scan examinations. This tool will flag potential urgent examinations allowing prioritisation of reporting based on clinical priority as opposed to chronological allocation. The tool will also highlight potentially critical findings to reporters, which can be integrated into their diagnoses. The tool will be trialed and implemented to augment Medica's urgent, out-of-hours NightHawk service.
The second area is to co-develop a bespoke AI-based automated workflow improvement tool that aims to improve the efficiency of study allocation from NHS clients to Medica's network of over 435 reporters.
Stuart Quin, Chief Executive Officer of Medica commented:
'Medica has been actively following the development of decision support tools using artificial intelligence to better understand the benefit to our clients. As we indicated in September 2019, our focus has been on areas that can have an immediate improvement to workflow and can support clinical decision making. As a leader in artificial intelligence solutions for radiology with an impressive track record of successful deployment in teleradiology workflows, backed up by peer-reviewed studies, Qure.ai is an ideal partner.'
Prashant Warier, Chief Executive Officer of Qure.ai commented:
'We are excited to partner with Medica, the UK's leading provider of teleradiology reporting, and we look forward to working with their team to realise the benefits of artificial intelligence in this important market. The tools being developed for Medica will improve efficiencies and support their strong network of highly skilled radiologists and radiographers.'
For further information, please contact:
Stuart Quin, Chief Executive Officer
Kevin Terrins, Business Development Director
+44 (0)33 33 111 222
Prashant Warier, Chief Executive Officer
Rohit Ghosh, Business Development Director
Victoria Foster Mitchell
+44 (0)20 3727 1000
About Medica Group PLC
Medica is the UK market leader in the provision of teleradiology services, providing outsourced interpretation and reporting on MRI (magnetic resonance imaging), CT (computerised tomography) and plain film (x-ray) images. The Company currently offers three primary services to hospital radiology departments: NightHawk, an out-of-hours service, routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.
Medica has developed a bespoke, secure IT platform that provides market-leading linkage between a hospital's radiology information system (RIS) and consultant radiologists who contract with Medica. Direct RIS access ensures that the full wider patient information is available and reviewed with every report.
The Company contracts with the largest pool of consultant radiologists outside of the NHS and has been trusted to provide more than 1.3 million examinations annually across its customer base of more than 100 NHS Trusts and various private hospital groups and diagnostic imaging companies.
For more information please visit www.medicagroup.co.uk.
Headquartered in Mumbai, India, with U.S. operations in San Francisco and New York, Qure.ai is a breakthrough Artificial Intelligence (AI) solution developer that is disrupting the radiology 'status quo' by enhancing imaging accuracy and improving health outcomes with the assistance of machine-supported tools. Qure.ai taps deep learning technology to provide automated interpretation of radiology exams like X-rays, CTs and MRI scans for time and resource-strapped medical imaging professionals-enabling faster diagnosis and speed to treatment. Qure.ai is helping make healthcare more accessible and affordable to patients worldwide.
For more information, please visit www.qure.ai.